PhaseBio Pharmaceuticals Inc
NASDAQ:PHAS
Income Statement
Earnings Waterfall
PhaseBio Pharmaceuticals Inc
Revenue
|
818k
USD
|
Operating Expenses
|
-105m
USD
|
Operating Income
|
-104.2m
USD
|
Other Expenses
|
1.4m
USD
|
Net Income
|
-102.8m
USD
|
Income Statement
PhaseBio Pharmaceuticals Inc
Jun-2018 | Sep-2018 | Dec-2018 | Mar-2019 | Jun-2019 | Sep-2019 | Dec-2019 | Mar-2020 | Jun-2020 | Sep-2020 | Dec-2020 | Mar-2021 | Jun-2021 | Sep-2021 | Dec-2021 | Mar-2022 | Jun-2022 | ||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | ||||||||||||||||||
Revenue |
0
N/A
|
0
N/A
|
1
+63%
|
1
+97%
|
2
+53%
|
2
-8%
|
2
+27%
|
2
-14%
|
1
-35%
|
1
-18%
|
0
-70%
|
0
N/A
|
10
N/A
|
11
+3%
|
11
+1%
|
11
+1%
|
1
-93%
|
|
Operating Income | ||||||||||||||||||
Operating Expenses |
(11)
|
(15)
|
(20)
|
(25)
|
(32)
|
(38)
|
(42)
|
(49)
|
(63)
|
(71)
|
(85)
|
(96)
|
(104)
|
(112)
|
(118)
|
(111)
|
(105)
|
|
Selling, General & Administrative |
(3)
|
(3)
|
(5)
|
(7)
|
(8)
|
(10)
|
(11)
|
(12)
|
(13)
|
(13)
|
(13)
|
(13)
|
(14)
|
(15)
|
(16)
|
(17)
|
(17)
|
|
Research & Development |
(9)
|
(12)
|
(15)
|
(19)
|
(24)
|
(28)
|
(31)
|
(37)
|
(50)
|
(58)
|
(72)
|
(83)
|
(89)
|
(97)
|
(102)
|
(94)
|
(88)
|
|
Operating Income |
(11)
N/A
|
(14)
-27%
|
(20)
-36%
|
(24)
-23%
|
(30)
-22%
|
(36)
-22%
|
(40)
-10%
|
(47)
-17%
|
(61)
-31%
|
(70)
-15%
|
(85)
-21%
|
(96)
-13%
|
(93)
+3%
|
(101)
-9%
|
(107)
-6%
|
(100)
+7%
|
(104)
-4%
|
|
Pre-Tax Income | ||||||||||||||||||
Interest Income Expense |
(5)
|
(5)
|
(4)
|
(3)
|
(1)
|
1
|
0
|
(0)
|
(5)
|
(9)
|
(14)
|
(15)
|
(17)
|
(15)
|
(22)
|
(13)
|
1
|
|
Total Other Income |
(0)
|
(2)
|
0
|
0
|
1
|
3
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
Pre-Tax Income |
(16)
N/A
|
(22)
-33%
|
(24)
-11%
|
(27)
-12%
|
(29)
-10%
|
(33)
-12%
|
(39)
-20%
|
(47)
-19%
|
(66)
-40%
|
(80)
-21%
|
(99)
-24%
|
(111)
-13%
|
(110)
+1%
|
(117)
-6%
|
(129)
-11%
|
(113)
+13%
|
(103)
+9%
|
|
Net Income | ||||||||||||||||||
Tax Provision |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
(2)
|
(2)
|
(2)
|
0
|
0
|
|
Income from Continuing Operations |
(16)
|
(22)
|
(24)
|
(27)
|
(29)
|
(33)
|
(39)
|
(47)
|
(66)
|
(80)
|
(99)
|
(111)
|
(112)
|
(118)
|
(131)
|
(115)
|
(103)
|
|
Net Income (Common) |
(16)
N/A
|
(22)
-33%
|
(24)
-11%
|
(27)
-12%
|
(29)
-10%
|
(33)
-12%
|
(39)
-20%
|
(47)
-19%
|
(66)
-40%
|
(80)
-21%
|
(99)
-24%
|
(111)
-13%
|
(112)
0%
|
(118)
-6%
|
(131)
-11%
|
(115)
+12%
|
(103)
+10%
|
|
EPS (Diluted) |
-0.42
N/A
|
-0.88
-110%
|
-0.97
-10%
|
-1.09
-12%
|
-1.05
+4%
|
-1.14
-9%
|
-1.36
-19%
|
-1.63
-20%
|
-2.28
-40%
|
-2.72
-19%
|
-3.35
-23%
|
-3.55
-6%
|
-2.32
+35%
|
-2.46
-6%
|
-2.72
-11%
|
-2.36
+13%
|
-2.09
+11%
|